Company: BDRX
Filing Date: 2025-05-08
Form Type: POS AM
Source: 0001214659-25-007201
Chunk: 123

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-08
Form: POS AM
Chunk 123
---
 connection with the
transactions contemplated by the Warrant Agreements, we issued an aggregate of 124,181 Depositary Shares to certain holders of our Series
E Warrants and Series F Warrants, upon the exercise of 62,906 Series E Warrants and 61,275 Series F Warrants, at an exercise price of
$37.50 per share. In addition, we issued to such holders an aggregate of 94,358 Series G warrants, or the Series G Warrants, and 147,805
Series H warrants, or the Series H Warrants. The aggregate gross proceeds to the Company were approximately $6.05 million, before deducting
agent fees and expenses. Additionally, we issued warrants to purchase 6,456 of our Depositary Shares in connection with the offering to
Ladenburg, as agent, and certain designees of Ladenburg, or Warrant Agent Warrants.

On July 22, 2024, we completed the Offerings with the Investors, pursuant to which we sold in the Registered Direct Offering an aggregate of (i) 202,032 Depositary Shares and (ii) 11,157 July 2024 Pre-Funded Warrants, at a price per Depositary Share of $0.94, and a price per July 2024 Pre-Funded Warrant of $23.4975, and in the concurrent July 2024 Private Placement, we issued and sold to the Investors (x) Series J Warrants exercisable for 213,188 Depositary Shares, and (y) Series K Warrants to purchase an aggregate of 213,188 Depositary Shares. The warrants are immediately exercisable at an exercise price of $25.00 per Depositary Share, subject to adjustments for certain dilutive equity issuances. The aggregate gross proceeds to the Company were approximately $5.0 million. Additionally, we issued July 2024 Placement Agent Warrants to purchase 8,525 of our Depositary Shares in connection with the offering to Ladenburg and certain designees of Ladenburg.

| Item 8. | Exhibits and Financial Statement 
 Schedules                        |

| (a) | The Exhibit Index is incorporated 
 herein by reference.              |

See the Exhibit Index attached to this registration
statement, which is incorporated herein by reference.

| (b) | Financial Statement Schedules. |

Schedules not listed above have been omitted
because the information required to be set forth therein is not applicable or is shown in the financial statements